戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 events toxicity induced by the Lxr inhibitor geranylgeranyl pyrophosphate.
2 erase inhibitor and blocked by coexposure to geranylgeranyl pyrophosphate.
3 ransferase inhibitors and by the addition of geranylgeranyl pyrophosphate.
4 und to be reversible on supplementation with geranylgeranyl pyrophosphate.
5 d endothelial apoptosis and were reversed by geranylgeranyl pyrophosphate.
6  at high concentrations that are reversed by geranylgeranyl pyrophosphate.
7 t imposed by statins was corrected by adding geranylgeranyl pyrophosphate.
8 esence of farnesyl pyrophosphate (10 muM) or geranylgeranyl pyrophosphate (10 muM).
9 [(3)H]geranylgeranyl monophosphate and [(3)H]geranylgeranyl pyrophosphate ([(3)H]GG-P-P) in CTP-depen
10       Addition of mevalonate (200 microM) or geranylgeranyl pyrophosphate (5 microM) reversed the inh
11 ects were absent in slices co-incubated with geranylgeranyl pyrophosphate, a mevalonate product that
12                                              Geranylgeranyl pyrophosphate, a non-sterol intermediate
13     This inhibitory effect was reversed with geranylgeranyl pyrophosphate, an isoprenoid intermediate
14 ation and was employed for detection of both geranylgeranyl pyrophosphate and a secondary oxysterol s
15 ibitor lovastatin depletes cellular pools of geranylgeranyl pyrophosphate and farnesol pyrophosphate
16 rations of isoprenoid intermediates, such as geranylgeranyl pyrophosphate and farnesyl pyrophosphate.
17 cretion and mRNA levels, effects reversed by geranylgeranyl pyrophosphate and mimicked by inhibiting
18 mevalonate and by the downstream isoprenoid, geranylgeranyl pyrophosphate and not by farnesyl pyropho
19                                              Geranylgeranyl pyrophosphate appears to reduce ABCA1 exp
20 revented by mevalonate and by the isoprenoid geranylgeranyl pyrophosphate but not by cholesterol.
21 to simvastatin were blocked by mevalonate or geranylgeranyl pyrophosphate but not by farnesyl pyropho
22 nthesis pathway intermediates mevalonate and geranylgeranyl pyrophosphate but not squalene, indicatin
23 f simvastatin was reversed by mevalonate and geranylgeranyl pyrophosphate but not squalene, indicatin
24          Supplementation with mevalonate and geranylgeranyl pyrophosphate, but not farnesyl pyrophosp
25 ersed by cotreatment with mevalonolactone or geranylgeranyl-pyrophosphate, but not by farnesyl-pyroph
26  molecules including farnesyl pyrophosphate, geranylgeranyl pyrophosphate, cholesterol, and oxysterol
27 nprecedented evidence that-like immune cells-geranylgeranyl-pyrophosphate depletion and thus inhibiti
28                                              Geranylgeranyl pyrophosphate derived from heterologous b
29        Supplementation of culture media with geranylgeranyl pyrophosphate dramatically reversed the l
30 , farnesyl pyrophosphate (farnesyl-P-P), and geranylgeranyl pyrophosphate (geranylgeranyl-P-P).
31 both geranylgeranyl and farnesyl groups from geranylgeranyl pyrophosphate (GGPP) and farnesyl pyropho
32 isoprenoids farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) are synthetic precur
33 he isoprenyl precursors, mevalonic acid, and geranylgeranyl pyrophosphate (GGpp) attenuated the stati
34 fer with a lower efficiency than FPP whereas geranylgeranyl pyrophosphate (GGPP) does not transfer at
35 trations of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) in cultured cells.
36 nce that the FPP-derived, 20-carbon molecule geranylgeranyl pyrophosphate (GGPP) is a potent endogeno
37      Synthesis of the metabolic intermediate geranylgeranyl pyrophosphate (GGPP) is required to speci
38 cessing and prevents RhoB upregulation while geranylgeranyl pyrophosphate (GGPP) restores Rap1a proce
39 in-containing protein-1 (UBIAD1), which uses geranylgeranyl pyrophosphate (GGpp) to synthesize the vi
40 omain-containing protein-1 (UBIAD1) utilizes geranylgeranyl pyrophosphate (GGpp) to synthesize the vi
41 aused by mutations in UBIAD1, which utilizes geranylgeranyl pyrophosphate (GGpp) to synthesize vitami
42 ferase domain-containing protein-1) utilizes geranylgeranyl pyrophosphate (GGpp) to synthesize vitami
43                   The effects of mevalonate, geranylgeranyl pyrophosphate (GGPP), and farnesyl pyroph
44 d by farnesyl pyrophosphate (FPP) but not by geranylgeranyl pyrophosphate (GGPP), implicating perturb
45 trong anion dependence were competitive with geranylgeranyl pyrophosphate (GGPP), rather than with th
46 metabolites farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), which are used for
47 in this article that downstream depletion of geranylgeranyl pyrophosphate (GGPP), which is required f
48 evels of cholesterol and isoprenoids such as geranylgeranyl pyrophosphate (GGPP).
49 bited by the upstream non-sterol isoprenoid, geranylgeranyl pyrophosphate (GGPP).
50 he acetate/mevalonic acid pathway leading to geranylgeranyl pyrophosphate (GGPP).
51 r mutant, 2-fold) of the immediate precursor geranylgeranyl pyrophosphate (GGPP).
52 rol and many nonsterol isoprenoids including geranylgeranyl pyrophosphate (GGpp).
53 the presence or absence of mevalonate (MVA), geranylgeranyl-pyrophosphate (GGPP) and farnesyl-pyropho
54           We demonstrate that the isoprenoid geranylgeranyl-pyrophosphate (GGPP) mediates proliferati
55 substrates (farnesyl pyrophosphate [FPP] and geranylgeranyl pyrophosphate [GGPP]).
56 are completely reversed by mevalonate and by geranylgeranyl pyrophosphate, implicating geranylgeranyl
57 oli, to esterify bacteriochlorophyllide with geranylgeranyl pyrophosphate in vitro, thereby generatin
58 y characterized step being the conversion of geranylgeranyl pyrophosphate into casbene.
59 Pases with isoprenoid molecules derived from geranylgeranyl pyrophosphate or farnesyl pyrophosphate i
60           Supplementation with mevalonate or geranylgeranyl pyrophosphate prevented, whereas inhibiti
61  by cholesterol biosynthesis in part through geranylgeranyl pyrophosphate production and substrate pr
62 n of isoprenoids (farnesyl-pyrophosphate and geranylgeranyl-pyrophosphate) rather than cholesterol in
63 t Hmg2 degradation is the 20-carbon isoprene geranylgeranyl pyrophosphate, rather than a sterol.
64                      However, treatment with geranylgeranyl pyrophosphate resulted in a dose- and tim
65                             L-Mevalonate and geranylgeranyl pyrophosphate reversed the effect, confir
66                                              Geranylgeranyl pyrophosphate selectively enhanced the de
67  of transcription 1), a downstream target of geranylgeranyl pyrophosphate signaling, was enhanced.
68  12% identical amino acid sequences with the geranylgeranyl pyrophosphate synthase (GGPPS) of fungi,
69 ur-BP, respectively) inhibitors of the human geranylgeranyl pyrophosphate synthase (hGGPPS) were desi
70 ibed that are potent inhibitors of the human geranylgeranyl pyrophosphate synthase (hGGPPS).
71 mal membrane 22PMP, the mammalian homolog of geranylgeranyl pyrophosphate synthase, an mRNA related t
72 ere we report the crystal structure of human geranylgeranyl pyrophosphate synthase, the first mammali
73                Alternatively, establishing a geranylgeranyl pyrophosphate synthase-mediated flux flow
74  enzymes farnesyl pyrophosphate synthase and geranylgeranyl pyrophosphate synthase.
75 or the inhibition of tube formation, whereas geranylgeranyl pyrophosphate, the substrate for the gera
76              In particular, the synthesis of geranylgeranyl pyrophosphate through the 3-hydroxy-3-met
77                     Supply of the isoprenoid geranylgeranyl pyrophosphate to oAbeta(42)-treated neuro
78                                  Addition of geranylgeranyl pyrophosphate to the culture medium resto
79 imvastatin was blocked after incubation with geranylgeranyl-pyrophosphate to circumvent loss of isopr
80 ication by regulating the cellular levels of geranylgeranyl pyrophosphate, we demonstrate that the im
81 or farnesyl pyrophosphate and its derivative geranylgeranyl pyrophosphate were also increased in the